Dilated Cardiomyopathy Therapeutic Market

Dilated cardiomyopathy (DCM) is characterized by LV (left ventricular) or biventricular systolic dysfunction and dilation, not explained by abnormal loading conditions or coronary artery disease.
Dilated Cardiomyopathy Therapeutic Market contains market size and forecasts of Dilated Cardiomyopathy Therapeutic in Global, including the following market information:

• Global Dilated Cardiomyopathy Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Dilated Cardiomyopathy Therapeutic market was valued at 328.7 million in 2021 and is projected to reach US$ 423.4 million by 2028, at a CAGR of 3.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Aldosterone antagonists Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Dilated Cardiomyopathy Therapeutic include Array BioPharma, Inc., AstraZeneca plc., Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc. and Sanofi S.A., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Dilated Cardiomyopathy Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dilated Cardiomyopathy Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Dilated Cardiomyopathy Therapeutic Market Segment Percentages, by Type, 2021 (%)

• Aldosterone antagonists
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin II receptor blockers (ARBs)
• Beta-blockers

Global Dilated Cardiomyopathy Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Dilated Cardiomyopathy Therapeutic Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Academic Institutions

Global Dilated Cardiomyopathy Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Dilated Cardiomyopathy Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Dilated Cardiomyopathy Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Dilated Cardiomyopathy Therapeutic revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Array BioPharma, Inc.
• AstraZeneca plc.
• Celladon Corporation
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc. (J&J)
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Vericel Corporation

To know more about market statistics, Download a FREE Sample copy